Placebo to salmeterol
Sponsors
Novartis Pharmaceuticals, Novartis, Boehringer Ingelheim
Conditions
AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive
Phase 3
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
CompletedNCT00529529
Start: 2007-09-30End: 2008-08-31Updated: 2011-08-29
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
CompletedNCT00567996
Start: 2007-11-30Updated: 2011-08-18
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00615030
Start: 2008-01-31End: 2008-08-31Updated: 2011-08-17
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00821093
Start: 2009-01-31End: 2009-10-31Updated: 2011-08-18
Efficacy and Safety of Different Doses of Indacaterol
CompletedNCT01079130
Start: 2010-02-28Updated: 2011-08-19
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01089127
Start: 2010-03-31End: 2010-07-31Updated: 2011-08-19
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02172794
Start: 2002-05-31Updated: 2018-08-31